A series of new copper(II) complexes were prepared. They are [CuL1(NCS)] (1), [CuClL1]·CH3OH (2), [CuClL2]·CH3OH (3), [CuL3(NCS)]·CH3OH (4), [CuL4(NCS)]·0.4H2O (5), and [CuL5(bipy)] (6), where L1, L2, L3 and L4 are the deprotonated form of N′-(2-hydroxybenzylidene)-3-methylbenzohydrazide, 4-bromo-N′-(2-hydroxy-5-methoxybenzylidene)benzohydrazide, N′-(2-hydroxy-5-methoxybenzylidene)-3-methylbenzohydrazide and 2-chloro-N′-(2-hydroxy-5-methoxybenzylidene)benzohydrazide, respectively, L5 is the dianionic form of N′-(2-hydroxybenzylidene)-3-methylbenzohydrazide, and bipy is 2,2′-bipyridine. The complexes were characterized by infrared and UV–Vis spectra and single crystal X-ray diffraction. The Cu atoms in complexes 1, 2, 3, 4 and 5 are coordinated by the NOO donor set of the aroylhydrazone ligands, and one Cl or thiocyanate N atom, forming square planar coordination. The Cu atom in complex 6 is in a square pyramidal coordination, with the NOO donor set of L1, and one N atom of bipy defining the basal plane, and with the other N atom of bipy occupying the apical position. Complexes 1, 2, 3, 4 and 5 show effective urease inhibitory activities, with IC50 values of 5.14, 0.20, 4.06, 5.52 and 0.26μM, respectively. Complex 6 has very weak activity against urease, with IC50 value over 100μM. Molecular docking study of the complexes with the Helicobacter pylori urease was performed. The relationship between structures and urease inhibitory activities indicated that copper complexes with square planar coordination are better models for urease inhibition.
Read full abstract